Synthesis and in vitro activities on anti-platelet aggregation of 4-methoxy-1,3-phthalamidesamides and benzenedisulfonamides
- 9 Downloads
Cardiovascular diseases are the most frequent cause of morbidity and mortality worldwide. In order to discover novel compounds with anti-platelet aggregation activities, a series of novel 4-methoxy-1,3-phthalamidesamides (1a–1i) and a series of novel 4-methoxy-1,3-benzenedisulfon-amides (2a–2i) were synthesized and their anti-platelet aggregation activities were evaluated by the turbidimetric method in response to the following agonists: adenosine diphosphate (ADP), arachidonic acid (AA), and Collagen. Those compounds that have better in vitro activities were subjected to cell toxicity tests via cell counting kit-8 (CCK-8) assay. The inhibition rates of anti-platelet in vitro of five compounds 1g (39.45%), 2d (38.87%), 2g (38.55%), 2h (44.56%), and 2i (43.93%) were higher than that of two reference drugs picotamide (36.12%) and aspirin (38.45%) when ADP was selected as an inducer. The inhibition rates of seven compounds 1c (43.63%), 1d (40.02%), 1g (47.42%), 1i (40.45%), 2c (40.11%), 2d (40.45%), and 2i (49.05%) were higher than that of picotamide (34.89%) and aspirin (39.43%) when AA was selected as inducer. And the inhibition rates of five compounds 1d (47.22%), 1i (45.01%), 2d (38.74%), 2e (42.21%), and 2f (39.94%) were higher than picotamide (38.45%) and aspirin (37.08%) when collagen was selected as inducer. Moreover, the effect of cell toxicity exhibited that none of the compounds had obvious cell toxicity against L-929 cells. Therefore, 4-methoxy-1,3-phthalamidesamides (1a–1i) and 4-methoxy-1,3-benzenedisulfon-amides (2a–2i) have the potential to become a novel kind of anti-platelet drugs and deserve further study.
Keywords4-Methoxy-1,3-phthal-amides 4-Methoxy-1,3-benzenedisulfon-amides Synthesis Picotamide Anti-platelet activity
The authors are grateful to the National Science Foundation of China (11341014) and the Committee of Science and Technology of Tianjin of China (15JCZDJC33100) for the financial supports and Shenyang Pharmaceutical University of China for running platelet aggregation assays.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- Liu XJ, Wang CQ, Wang X, Zhang QX, Liu K (2016) Synthesis and antiplatelet aggregation activities in vitro of N,N-di(3-substitutedphenyl)-4-methoxyl benzene-1,3-disulfonamides. J Pharm Pharm Sci 4:72–76Google Scholar
- Liu XJ, Wang CQ, Meng J, Shi XX, Yan YN, Liu XG (2017) Design, synthesis and biological evaluation of 4-methoxy diaryl isophthalates as anti-platelet agents. Med Chem Res 1:1–9Google Scholar
- Wang Y, Wang X, Chen X, Liu XJ (2018) Synthesis and in vitro anti-platelet aggregation activities of 2-methoxy-5-arylamido-N-(pyridin-3-yl-methyl)benzamides. Arch Pharm (Weinheim) 352(1):e1800257Google Scholar